Magnetic resonance imaging (MRI) sensitivity and specificity seem to be less studied in enthesitis-related arthritis (ERA).
We aimed to determine the ability of sacroiliac MRI to diagnose ERA patients.
Materials and methods
We conducted a retrospective study including 44 patients with juvenile idiopathic arthritis (JIA). Each patient had a sacroiliac joint MRI. We divided patients into two groups: G1 patients with ERA and G2 patients with non-ERA subtype.
Results
ERA was noted in 61% of the cases. Sacroiliac joints were painful in 15 patients (34%). MRI was normal in 25 patients (57%) (G1:11 versus G2:14) and showed bone marrow edema in the sacroiliac joints in 19 patients (34%) (G1 = 16 versus G2 = 3, p = 0.005).
Sacroiliac joints MRI's sensitivity and specificity in the ERA diagnosis were 61.54% and 82.35%, respectively. Positive and negative predictive values were 84.21% and 58.33%, respectively. Furthermore, sacroiliac joint pain in the clinical examination was able to predict sacroiliac bone edema in MRI with an odds ratio of 6.8 (95% CI 1.68–28.09; p = 0.006).
Conclusion
Our study showed that sacroiliac joint MRI has good specificity and positive predictive value in the diagnosis of ERA patients among JIA patients. This underlines the usefulness of sacroiliac joint MRI in the early diagnosis of ERA patients.
导言和目标磁共振成像(MRI)的敏感性和特异性在关节炎相关性关节炎(ERA)中的研究似乎较少。我们旨在确定骶髂关节 MRI 诊断ERA 患者的能力。每位患者都进行了骶髂关节磁共振成像检查。我们将患者分为两组:结果 61%的病例发现ERA。15例患者(34%)骶髂关节疼痛。25 名患者(57%)(G1:11 对 G2:14)磁共振成像正常,19 名患者(34%)(G1 = 16 对 G2 = 3,P = 0.005)骶髂关节磁共振成像在 ERA 诊断中的敏感性和特异性分别为 61.54% 和 82.35%。骶髂关节磁共振成像对 ERA 诊断的敏感性和特异性分别为 61.54% 和 82.35%,阳性预测值和阴性预测值分别为 84.21% 和 58.33%。此外,临床检查中的骶髂关节疼痛能够预测 MRI 中的骶髂骨水肿,其几率比为 6.8 (95% CI 1.68-28.09; p = 0.006)。这凸显了骶髂关节磁共振成像在ERA患者早期诊断中的作用。
{"title":"Does sacroiliitis is a mandatory criterion for enthesitis-related arthritis diagnosis?","authors":"Hanene Lassoued Ferjani , Lobna Kharrat , Dorra Ben Nessib , Dhia Kaffel , Kaouther Maatallah , Wafa Hamdi","doi":"10.1016/j.reuma.2023.12.005","DOIUrl":"10.1016/j.reuma.2023.12.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Magnetic resonance imaging (MRI) sensitivity and specificity seem to be less studied in enthesitis-related arthritis (ERA).</p><p>We aimed to determine the ability of sacroiliac MRI to diagnose ERA patients.</p></div><div><h3>Materials and methods</h3><p>We conducted a retrospective study including 44 patients with juvenile idiopathic arthritis (JIA). Each patient had a sacroiliac joint MRI. We divided patients into two groups: G1 patients with ERA and G2 patients with non-ERA subtype.</p></div><div><h3>Results</h3><p>ERA was noted in 61% of the cases. Sacroiliac joints were painful in 15 patients (34%). MRI was normal in 25 patients (57%) (G1:11 versus G2:14) and showed bone marrow edema in the sacroiliac joints in 19 patients (34%) (G1<!--> <!-->=<!--> <!-->16 versus G2<!--> <!-->=<!--> <!-->3, <em>p</em> <!-->=<!--> <!-->0.005).</p><p>Sacroiliac joints MRI's sensitivity and specificity in the ERA diagnosis were 61.54% and 82.35%, respectively. Positive and negative predictive values were 84.21% and 58.33%, respectively. Furthermore, sacroiliac joint pain in the clinical examination was able to predict sacroiliac bone edema in MRI with an odds ratio of 6.8 (95% CI 1.68–28.09; <em>p</em> <!-->=<!--> <!-->0.006).</p></div><div><h3>Conclusion</h3><p>Our study showed that sacroiliac joint MRI has good specificity and positive predictive value in the diagnosis of ERA patients among JIA patients. This underlines the usefulness of sacroiliac joint MRI in the early diagnosis of ERA patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 187-192"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139538619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.09.010
Francisco José Nicolás-Sánchez , Lluis Eleuteri Pons I Ferré , Francesc Josep Nicolás-Sarrat , Alberto González Barranquero
{"title":"La p.(Tyr135His), una nueva variante asociada a la fiebre mediterránea familiar","authors":"Francisco José Nicolás-Sánchez , Lluis Eleuteri Pons I Ferré , Francesc Josep Nicolás-Sarrat , Alberto González Barranquero","doi":"10.1016/j.reuma.2023.09.010","DOIUrl":"10.1016/j.reuma.2023.09.010","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 226-227"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135850287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.12.001
Clara Moriano Morales , Jenaro Graña Gil , Noé Brito García , José Luis Martín Varillas , Vanesa Calvo del Río , Patricia Moya Alvarado , Francisco Javier Narváez García , Gerard Espinosa , Petra Díaz del Campo Fontecha , Mercedes Guerra Rodríguez , José Mateo Arranz , Manuela López Gómez , Félix Manuel Francisco Hernández , M. Mar Trujillo , Raquel dos Santos Sobrín , Juan Ignacio Martín Sánchez , Jesús Maese Manzano , Julio Suárez Cuba
Objective
To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (difficult to treat, severe resistant, severe relapse) to conventional treatment.
Methods
A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format –patient, intervention, comparison and outcome–. Systematic reviews of the evidence were conducted; the quality of the evidence was evaluated following the methodology of the international working group Grading of Recommendations, Assessment, Development, and Evaluation. After that, the multidisciplinary panel formulated the specific recommendations.
Results
Four PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with Behçet's syndrome with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus.
Conclusions
The treatment of most severe clinical manifestations of Behçet's syndrome lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.
{"title":"Recomendaciones SER sobre el tratamiento del síndrome de Behçet refractario","authors":"Clara Moriano Morales , Jenaro Graña Gil , Noé Brito García , José Luis Martín Varillas , Vanesa Calvo del Río , Patricia Moya Alvarado , Francisco Javier Narváez García , Gerard Espinosa , Petra Díaz del Campo Fontecha , Mercedes Guerra Rodríguez , José Mateo Arranz , Manuela López Gómez , Félix Manuel Francisco Hernández , M. Mar Trujillo , Raquel dos Santos Sobrín , Juan Ignacio Martín Sánchez , Jesús Maese Manzano , Julio Suárez Cuba","doi":"10.1016/j.reuma.2023.12.001","DOIUrl":"10.1016/j.reuma.2023.12.001","url":null,"abstract":"<div><h3>Objective</h3><p>To develop multidisciplinary recommendations based on available evidence and expert consensus for the therapeutic management of patients with refractory Behçet's syndrome (difficult to treat, severe resistant, severe relapse) to conventional treatment.</p></div><div><h3>Methods</h3><p>A group of experts identified clinical research questions relevant to the objective of the document. These questions were reformulated in PICO format –patient, intervention, comparison and outcome–. Systematic reviews of the evidence were conducted; the quality of the evidence was evaluated following the methodology of the international working group <em>Grading of Recommendations, Assessment, Development, and Evaluation</em>. After that, the multidisciplinary panel formulated the specific recommendations.</p></div><div><h3>Results</h3><p>Four PICO questions were selected regarding the efficacy and safety of systemic pharmacological treatments in patients with Behçet's syndrome with clinical manifestations refractory to conventional therapy related to mucocutaneous and/or articular, vascular, neurological parenchymal and gastrointestinal phenotypes. A total of 7 recommendations were made, structured by question, based on the identified evidence and expert consensus.</p></div><div><h3>Conclusions</h3><p>The treatment of most severe clinical manifestations of Behçet's syndrome lacks solid scientific evidence and, besides, there are no specific recommendation documents for patients with refractory disease. With the aim of providing a response to this need, here we present the first official recommendations of the Spanish Society of Rheumatology for the management of these patients. They are devised as a tool for assistance in clinical decision making, therapeutic homogenisation and to reduce variability in the care of these patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 204-217"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139395267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.09.006
Ariana Ringer , Andrea María Smichowski , José Maximiliano Martínez Pérez , Ignacio Javier Gandino
{"title":"The Latin-American rheumatology community needs to put the eye on ocular cicatricial pemphigoid","authors":"Ariana Ringer , Andrea María Smichowski , José Maximiliano Martínez Pérez , Ignacio Javier Gandino","doi":"10.1016/j.reuma.2023.09.006","DOIUrl":"10.1016/j.reuma.2023.09.006","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 227-228"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135606991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.12.006
Javier Fernández-Torres , Víctor Ilizaliturri-Sánchez , Karina Martínez-Flores , Carlos Alberto Lozada-Pérez , Rolando Espinosa-Morales , Yessica Zamudio-Cuevas
Background
The characteristics of synovial fluid (SF) in geriatric patients differ from those in younger patients. In Mexico, epidemiologic data on the incidence of different rheumatic diseases in geriatric patients are scarce.
Objective
To describe the physical characteristics of geriatric SF and the prevalence of crystals in knee and other joint aspirates from patients with previously diagnosed joint disease.
Materials and methods
A retrospective study was performed with a baseline of 517 SF samples between 2011 and 2023. White blood cell count was performed by Neubauer chamber and crystals were identified by polarized light microscopy. Descriptive statistical analysis was performed and prevalence was reported as a percentage.
Results
The mean age of the adults was 73.5 ± 5.0 years, 54.4% were women and 45.6% were men. The mean SF volume was 6.3 ± 9.5 mL in older adults and 15.3 ± 24.9 mL in those younger than 65 years. The mean viscosity in older adults was 9.5 ± 4.5 mm and the mean leukocyte count was 7352 ± 16,402 leukocytes/mm3. Seventy percent of the older adults’ SFs were referred to the laboratory for osteoarthritis (OA), with lower proportions for rheumatoid arthritis (RA) (14.6%) and gout (5.1%). Of the crystals observed in the geriatric population, 14.6% corresponded to monosodium urate crystals (CUM) and 18.9% to calcium pyrophosphate crystals (CPP).
Conclusions
The characteristics of LS in older adults were smaller volume, increased viscosity, and non-inflammatory. The main diagnoses were OA, RA, and gout. The crystal content of the SF of the geriatric population corresponded mainly to CPP.
背景老年患者滑液(SF)的特征与年轻患者不同。在墨西哥,有关老年患者中不同风湿性疾病发病率的流行病学数据很少。目的描述老年患者滑液的物理特征以及既往确诊关节疾病患者膝关节和其他关节抽吸物中晶体的流行率。白细胞计数由 Neubauer 室进行,晶体由偏振光显微镜鉴定。结果成人的平均年龄为(73.5 ± 5.0)岁,54.4%为女性,45.6%为男性。老年人的平均 SF 容量为 6.3 ± 9.5 mL,65 岁以下的平均 SF 容量为 15.3 ± 24.9 mL。老年人的平均粘度为 9.5 ± 4.5 毫米,平均白细胞数为 7352 ± 16402 个/立方毫米。70%的老年人 SF 因骨关节炎(OA)而被转至实验室,类风湿性关节炎(RA)(14.6%)和痛风(5.1%)的比例较低。在老年人群中观察到的结晶中,14.6%为单钠尿酸盐结晶(CUM),18.9%为焦磷酸钙结晶(CPP)。主要诊断为 OA、RA 和痛风。老年人群 SF 中的晶体含量主要与 CPP 相对应。
{"title":"An update on the study of synovial fluid in the geriatric patient","authors":"Javier Fernández-Torres , Víctor Ilizaliturri-Sánchez , Karina Martínez-Flores , Carlos Alberto Lozada-Pérez , Rolando Espinosa-Morales , Yessica Zamudio-Cuevas","doi":"10.1016/j.reuma.2023.12.006","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.12.006","url":null,"abstract":"<div><h3>Background</h3><p>The characteristics of synovial fluid (SF) in geriatric patients differ from those in younger patients. In Mexico, epidemiologic data on the incidence of different rheumatic diseases in geriatric patients are scarce.</p></div><div><h3>Objective</h3><p>To describe the physical characteristics of geriatric SF and the prevalence of crystals in knee and other joint aspirates from patients with previously diagnosed joint disease.</p></div><div><h3>Materials and methods</h3><p>A retrospective study was performed with a baseline of 517 SF samples between 2011 and 2023. White blood cell count was performed by Neubauer chamber and crystals were identified by polarized light microscopy. Descriptive statistical analysis was performed and prevalence was reported as a percentage.</p></div><div><h3>Results</h3><p>The mean age of the adults was 73.5<!--> <!-->±<!--> <!-->5.0 years, 54.4% were women and 45.6% were men. The mean SF volume was 6.3<!--> <!-->±<!--> <!-->9.5<!--> <!-->mL in older adults and 15.3<!--> <!-->±<!--> <!-->24.9<!--> <!-->mL in those younger than 65 years. The mean viscosity in older adults was 9.5<!--> <!-->±<!--> <!-->4.5<!--> <!-->mm and the mean leukocyte count was 7352<!--> <!-->±<!--> <!-->16,402<!--> <!-->leukocytes/mm<sup>3</sup>. Seventy percent of the older adults’ SFs were referred to the laboratory for osteoarthritis (OA), with lower proportions for rheumatoid arthritis (RA) (14.6%) and gout (5.1%). Of the crystals observed in the geriatric population, 14.6% corresponded to monosodium urate crystals (CUM) and 18.9% to calcium pyrophosphate crystals (CPP).</p></div><div><h3>Conclusions</h3><p>The characteristics of LS in older adults were smaller volume, increased viscosity, and non-inflammatory. The main diagnoses were OA, RA, and gout. The crystal content of the SF of the geriatric population corresponded mainly to CPP.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 193-198"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.12.004
Isabel del Blanco Alonso, Álvaro Revilla Calavia, Laura Saiz-Viloria, Manuel Diez Martínez, Enrique San Norberto García, Carlos Vaquero Puerta
Temporal arteritis (TA) is the most common form of systemic vasculitis. Its diagnosis is based on criteria proposed by the American College of Rheumatology (1990), and its treatment is high-dose corticosteroids.
Our objective is to assess the cost of diagnosing TA, and secondarily, cost-effective analysis of different diagnostic strategies (clinical, biopsy, Doppler ultrasound) and therapeutic strategies (corticosteroid suspension).
Material and method
Observational, retrospective study has been carried out on patients with TA (2012–2021). Demographic data, comorbidities, signs and symptoms suggestive of TA were collected. TA was diagnosed with a score ≥3 according to American College of Rheumatoloy criteria (ACR-SCORE). The costs of diagnosis and treatment modification were analysed.
Results
Seventy-five patients have been included, median age 77 (46-87) years. Headache, temporal pain and jaw claudication were significant for the diagnosis of TA.
Patients with a halo on Doppler ultrasound and a positive biopsy have significantly elevated ESR and CRP compared to patients who do not.
The cost of the TA diagnosis was 414.7 euros/patient. If we use ACR-SCORE≥3-echodoppler it is 167.2 €/patient (savings 59.6%) and ACR-SCORE≥3-biopsy 339.75 €/patient (savings 18%). If the corticosteroid was removed and a biopsy was performed, 21.6 €/patient (94.7% savings), if the corticosteroid was removed and Doppler ultrasound was performed, 10.6 €/patient (97.4% savings).
Conclusions
Headache, temporary pain and jaw claudication are predictors of TA. Elevated ESR and CRP are predictors of positive biopsy and presence of halo on ultrasound.
The uses of ACR-SCORE≥3 with Doppler ultrasound or biopsy, and with corticosteroid suspension, are cost-effective.
{"title":"Análisis coste/efectivo del diagnóstico de la arteritis de la temporal","authors":"Isabel del Blanco Alonso, Álvaro Revilla Calavia, Laura Saiz-Viloria, Manuel Diez Martínez, Enrique San Norberto García, Carlos Vaquero Puerta","doi":"10.1016/j.reuma.2023.12.004","DOIUrl":"10.1016/j.reuma.2023.12.004","url":null,"abstract":"<div><p>Temporal arteritis (TA) is the most common form of systemic vasculitis. Its diagnosis is based on criteria proposed by the American College of Rheumatology (1990), and its treatment is high-dose corticosteroids.</p><p>Our objective is to assess the cost of diagnosing TA, and secondarily, cost-effective analysis of different diagnostic strategies (clinical, biopsy, Doppler ultrasound) and therapeutic strategies (corticosteroid suspension).</p></div><div><h3>Material and method</h3><p>Observational, retrospective study has been carried out on patients with TA (2012–2021). Demographic data, comorbidities, signs and symptoms suggestive of TA were collected. TA was diagnosed with a score ≥3 according to American College of Rheumatoloy criteria (ACR-SCORE). The costs of diagnosis and treatment modification were analysed.</p></div><div><h3>Results</h3><p>Seventy-five patients have been included, median age 77 (46-87) years. Headache, temporal pain and jaw claudication were significant for the diagnosis of TA.</p><p>Patients with a halo on Doppler ultrasound and a positive biopsy have significantly elevated ESR and CRP compared to patients who do not.</p><p>The cost of the TA diagnosis was 414.7 euros/patient. If we use ACR-SCORE≥3-echodoppler it is 167.2 €/patient (savings 59.6%) and ACR-SCORE≥3-biopsy 339.75 €/patient (savings 18%). If the corticosteroid was removed and a biopsy was performed, 21.6 €/patient (94.7% savings), if the corticosteroid was removed and Doppler ultrasound was performed, 10.6 €/patient (97.4% savings).</p></div><div><h3>Conclusions</h3><p>Headache, temporary pain and jaw claudication are predictors of TA. Elevated ESR and CRP are predictors of positive biopsy and presence of halo on ultrasound.</p><p>The uses of ACR-SCORE≥3 with Doppler ultrasound or biopsy, and with corticosteroid suspension, are cost-effective.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 181-186"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139631364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Henoch Schönlein purpura (HSP) and Kawasaki disease (KD) are two main inflammatory diseases among childhood vasculitis. Considering the anti-inflammatory effects of 25-hydroxyvitamin D3, we decided to investigate the association of serum 25-hydroxy vitamin D3 level with the type and severity of these conditions.
Materials and methods
The present study was performed as a historical cohort of 254 affected children with KD and HSP vasculitis. The required data were extracted, using a researcher-made questionnaire from patients’ electronic file, and then they were analyzed after collecting information of the patients.
Results
In HSP group, 54% of participants were boys. Similarly, in KD group, boys were more affected than girls. The comparative 25-hydroxyvitamin vitamin D3 level in HSP patients with and without renal involvement (P = 0.02), hematuria (P = 0.14), and in two groups with and without heart disease, and also with and without coronary artery dilatation in KD patients (P < 0.001) were significant.
Discussion and conclusions
The findings showed that insufficient level of vitamin D3 were significantly associated with the exacerbation of complications of both diseases, and therefore it seems that vitamin D deficiency can be an effective predictive factor of severity in HSP and KD patients.
{"title":"Investigating the comparative effect of vitamin D level with the type of complications in Henoch Schönlein purpura and Kawasaki disease","authors":"Mehrnoush Hassas Yeganeh , Reza Sinaei , Mitra Rouhi , Reza Shiari , Vadood Javadi Parvaneh , Khosro Rahmani , Erfan Sheikhbahaei","doi":"10.1016/j.reuma.2023.12.007","DOIUrl":"10.1016/j.reuma.2023.12.007","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Henoch Schönlein purpura (HSP) and Kawasaki disease (KD) are two main inflammatory diseases among childhood vasculitis. Considering the anti-inflammatory effects of 25-hydroxyvitamin D3, we decided to investigate the association of serum 25-hydroxy vitamin D3 level with the type and severity of these conditions.</p></div><div><h3>Materials and methods</h3><p>The present study was performed as a historical cohort of 254 affected children with KD and HSP vasculitis. The required data were extracted, using a researcher-made questionnaire from patients’ electronic file, and then they were analyzed after collecting information of the patients.</p></div><div><h3>Results</h3><p>In HSP group, 54% of participants were boys. Similarly, in KD group, boys were more affected than girls. The comparative 25-hydroxyvitamin vitamin D3 level in HSP patients with and without renal involvement (<em>P</em> <!-->=<!--> <!-->0.02), hematuria (<em>P</em> <!-->=<!--> <!-->0.14), and in two groups with and without heart disease, and also with and without coronary artery dilatation in KD patients (<em>P</em> <!--><<!--> <!-->0.001) were significant.</p></div><div><h3>Discussion and conclusions</h3><p>The findings showed that insufficient level of vitamin D3 were significantly associated with the exacerbation of complications of both diseases, and therefore it seems that vitamin D deficiency can be an effective predictive factor of severity in HSP and KD patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 199-203"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140407285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.12.003
Mona I. Nabih , Noha M. Khalil , Olfat Shaker , Mahmoud Ghanema , Sarah A. Hassan
Aim of the work
To evaluate serum brain-derived neurotrophic factor (BDNF) in Egyptian patients with rheumatoid arthritis (RA) and its relation with cognitive dysfunction.
Patients and methods
The study was carried out on 60 RA patients; 30 were active (group A) and 30 were non active (group B); and 30 controls (group C). RA disease activity was assessed via DAS28 tool, cognitive function via The Montreal Cognitive Assessment and depression via the PHQ depression scale. Serum BDNF levels were measured.
Results
The mean age in group A was 37.8 (± 9.37) years with 83.3% females, in group B was 39.97 (± 8.04) years with 86.7% females and in group C was 33.17 (± 3.6) years with 93.3% females. Abnormal cognitive functions test was detected in 66.7% of group A, 66.7% of group B, and in 23.3% of group C. There was a statistically significant difference in BDNF serum level between both groups of patients (1.58 ± 0.9 ng/ml for group A, 1.81 ± 1.17 ng/ml for group B) compared with the control group (3.01 ± 1.25 ng/ml, p < 0.001).
There was no statistically significant difference between BDNF and both disease duration and cognitive function, also no statistically significant difference regarding cognitive function, depression, and BNDF levels in patients with and without fibromyalgia. At a cut-off value of <2 ng/ml, BDNF detected RA patients with cognitive dysfunction with a sensitivity of 80%, specificity of 96.67%.
Conclusion
BDNF can be a potential biomarker of cognitive dysfunction in RA patients.
{"title":"Cognitive dysfunction, depression and serum level of brain-derived neurotrophic factor (BDNF) in Egyptian patients with rheumatoid arthritis","authors":"Mona I. Nabih , Noha M. Khalil , Olfat Shaker , Mahmoud Ghanema , Sarah A. Hassan","doi":"10.1016/j.reuma.2023.12.003","DOIUrl":"10.1016/j.reuma.2023.12.003","url":null,"abstract":"<div><h3>Aim of the work</h3><p>To evaluate serum brain-derived neurotrophic factor (BDNF) in Egyptian patients with rheumatoid arthritis (RA) and its relation with cognitive dysfunction.</p></div><div><h3>Patients and methods</h3><p><span>The study was carried out on 60 RA patients; 30 were active (group A) and 30 were non active (group B); and 30 controls (group C). RA disease activity was assessed via DAS28 tool, cognitive function via The Montreal Cognitive Assessment and depression via the </span>PHQ<span> depression scale. Serum BDNF levels were measured.</span></p></div><div><h3>Results</h3><p>The mean age in group A was 37.8 (±<!--> <!-->9.37) years with 83.3% females, in group B was 39.97 (±<!--> <!-->8.04) years with 86.7% females and in group C was 33.17 (±<!--> <!-->3.6) years with 93.3% females. Abnormal cognitive functions test was detected in 66.7% of group A, 66.7% of group B, and in 23.3% of group C. There was a statistically significant difference in BDNF serum level between both groups of patients (1.58<!--> <!-->±<!--> <!-->0.9<!--> <!-->ng/ml for group A, 1.81<!--> <!-->±<!--> <!-->1.17<!--> <!-->ng/ml for group B) compared with the control group (3.01<!--> <!-->±<!--> <!-->1.25<!--> <!-->ng/ml, <em>p</em> <!--><<!--> <!-->0.001).</p><p>There was no statistically significant difference between BDNF and both disease duration and cognitive function, also no statistically significant difference regarding cognitive function, depression, and BNDF levels in patients with and without fibromyalgia. At a cut-off value of <2<!--> <!-->ng/ml, BDNF detected RA patients with cognitive dysfunction with a sensitivity of 80%, specificity of 96.67%.</p></div><div><h3>Conclusion</h3><p>BDNF can be a potential biomarker of cognitive dysfunction in RA patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 175-180"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139455356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.reuma.2023.12.002
Pablo Arango Guerra , Santiago Monsalve Yepes , Andrés Chavarriaga Restrepo , Carlos Jaime Velasquez Franco
The use of specific antibodies in inflammatory myopathies has improved the characterization of this disease, identifying different clinical phenotypes. Patients with dermatomyositis and anti-MDA5 antibodies display typical skin symptoms, lesser muscular involvement, and a prevalence of interstitial lung disease of up to 91%. Beyond interstitial lung disease, spontaneous pneumomediastinum has been identified as a rare but potentially fatal pulmonary manifestation. Two cases of this complication in patients with anti-MDA5 dermatomyositis are reported.
{"title":"Neumomediastino espontáneo: una manifestación extramuscular de la dermatomiositis anti-MDA5. Reporte de 2 casos","authors":"Pablo Arango Guerra , Santiago Monsalve Yepes , Andrés Chavarriaga Restrepo , Carlos Jaime Velasquez Franco","doi":"10.1016/j.reuma.2023.12.002","DOIUrl":"10.1016/j.reuma.2023.12.002","url":null,"abstract":"<div><p>The use of specific antibodies in inflammatory myopathies has improved the characterization of this disease, identifying different clinical phenotypes. Patients with dermatomyositis and anti-MDA5 antibodies display typical skin symptoms, lesser muscular involvement, and a prevalence of interstitial lung disease of up to 91%. Beyond interstitial lung disease, spontaneous pneumomediastinum has been identified as a rare but potentially fatal pulmonary manifestation. Two cases of this complication in patients with anti-MDA5 dermatomyositis are reported.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 4","pages":"Pages 218-222"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139638326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.1016/j.reuma.2023.10.001
Mickael Essouma , Jan Rene Nkeck , Jean Jacques Noubiap
Background and aim
This was a systematic review and meta-analysis of the prevalence of thromboembolic events in children and adolescents with antiphospholipid syndrome (APS).
Methods
We searched PubMed, EMBASE and Web of Science to select relevant articles published between 1 January 2000 and 27 February 2022. We used the random-effects meta-analysis to estimate pooled point prevalence rates of thromboembolic events in studies with a minimum sample size of 30.
Results
We included five studies reporting data of 336 children and adolescents with primary APS and secondary APS (SAPS). Pooled point prevalence rates of initial general thrombosis, arterial thrombosis, venous thrombosis and stroke in individuals with seropositive APS were 98.2% (95% confidence interval [CI] 87.5–100), 27.6% (95% CI 21.4–34.2), 51.1% (95% CI 38.2–63.9) and 13.4% 95% CI (6.3–22.7), respectively. Pooled point prevalence rates of initial arterial and venous thromboses in children and adolescents with SAPS were 45.7% (95% CI 21.1–71.6) and 29.2% (95% CI 14.8–46), respectively.
Conclusion
Arterio-venous thromboembolism is highly frequent in children and adolescents with SAPS. More studies using thrombotic and non-thrombotic APS classification criteria are warranted to better assess the frequency and predictors of thromboembolism in age- and ancestry-diverse pediatric populations affected by different types of APS.
背景和目的这是一项关于抗磷脂综合征(APS)儿童和青少年血栓栓塞事件发生率的系统综述和荟萃分析。方法我们检索了PubMed、EMBASE和Web of Science,选择了2000年1月1日至2022年2月27日期间发表的相关文章。结果我们纳入了五项研究,这些研究报告了336名患有原发性APS和继发性APS(SAPS)的儿童和青少年的数据。在血清阳性 APS 患者中,初始一般血栓、动脉血栓、静脉血栓和中风的汇总点患病率分别为 98.2%(95% 置信区间 [CI] 87.5-100)、27.6%(95% CI 21.4-34.2)、51.1%(95% CI 38.2-63.9)和 13.4%(95% CI (6.3-22.7))。SAPS儿童和青少年最初动脉和静脉血栓形成的汇总点流行率分别为45.7%(95% CI 21.1-71.6)和29.2%(95% CI 14.8-46)。有必要使用血栓性和非血栓性APS分类标准进行更多研究,以更好地评估受不同类型APS影响的不同年龄和血统的儿科人群中血栓栓塞的频率和预测因素。
{"title":"Epidemiology of thromboembolic events in children and adolescents with antiphospholipid syndrome: A systematic review with meta-analysis","authors":"Mickael Essouma , Jan Rene Nkeck , Jean Jacques Noubiap","doi":"10.1016/j.reuma.2023.10.001","DOIUrl":"10.1016/j.reuma.2023.10.001","url":null,"abstract":"<div><h3>Background and aim</h3><p>This was a systematic review and meta-analysis of the prevalence of thromboembolic events in children and adolescents with antiphospholipid syndrome (APS).</p></div><div><h3>Methods</h3><p>We searched PubMed, EMBASE and Web of Science to select relevant articles published between 1 January 2000 and 27 February 2022. We used the random-effects meta-analysis to estimate pooled point prevalence rates of thromboembolic events in studies with a minimum sample size of 30.</p></div><div><h3>Results</h3><p>We included five studies reporting data of 336 children and adolescents with primary APS and secondary APS (SAPS). Pooled point prevalence rates of initial general thrombosis, arterial thrombosis, venous thrombosis and stroke in individuals with seropositive APS were 98.2% (95% confidence interval [CI] 87.5–100), 27.6% (95% CI 21.4–34.2), 51.1% (95% CI 38.2–63.9) and 13.4% 95% CI (6.3–22.7), respectively. Pooled point prevalence rates of initial arterial and venous thromboses in children and adolescents with SAPS were 45.7% (95% CI 21.1–71.6) and 29.2% (95% CI 14.8–46), respectively.</p></div><div><h3>Conclusion</h3><p>Arterio-venous thromboembolism is highly frequent in children and adolescents with SAPS. More studies using thrombotic and non-thrombotic APS classification criteria are warranted to better assess the frequency and predictors of thromboembolism in age- and ancestry-diverse pediatric populations affected by different types of APS.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 3","pages":"Pages 155-161"},"PeriodicalIF":1.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139824958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}